# Quinidine-Mexiletine-DDGI
Modeling of published quinidine-mexiletine-DDGI studies for model evaluation

## Repository files
Within this repository, we distribute a PK-Sim snapshot and a PK-Sim model file containing simulations of all published clinical studies used to evaluate the predictive performance of the quinidine model regarding quinidine-mexiletine-DDGIs, including the respective observed data digitized from literature reports. The applied mexiletine model has been published previously [1]. For further details and documentation please refer to [2].


## Version information

OSP Version 11.0

## License 
The model is distributed under the [GPLv2 Lincense](https://github.com/Open-Systems-Pharmacology/Suite/blob/develop/LICENSE).

## Reference
[[1] Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Gómez Mantilla JD, Nock V, Fleury A. A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug-drug-gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol, and caffeine. Pharmaceutics 2020;12(12):1191. DOI: 10.3390/pharmaceutics12121191.](https://pubmed.ncbi.nlm.nih.gov/33302490/)

[[2] Feick D, Rüdesheim S, Marok FZ, Selzer D, Loer HLH, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug–drug–gene interaction network. CPT Pharmacometrics Syst Pharmacol 2023. DOI: 10.1002/psp4.12981.](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.12981)
